WeWork’s dramatic fall from grace, which saw its valuation fall from $47 billion to a reported $8 billion amid an IPO fiasco, was just one example of a larger reckoning… Read More
Adaptive Biotechnologies has raised the price for its initial public offering, putting itself in a position to raise more cash than any other biotech IPO this year. The Seattle-based company,… Read More
Adaptive Biotechnologies, a high-flying startup that makes technology to read the human immune system, has officially filed to go public and seeks to raise $230 million from investors. Founded in… Read More